Evidence map›Paper›PMID 27777977›Full record

ArticleJCI insight2016

IP

Qingsong Lin, Guiling Zhao, Xi Fang, Xiaohong Peng, Huayuan Tang, Hong Wang, Ran Jing, Jie Liu, W Jonathan Lederer, Ju Chen and 1 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 71 citations in OpenAlex.

  1. Trial
  2. Review
  3. The role of IPPflugers Archiv : European journal of physiology · 2026
    Review
  4. Pacemaking in the lymphatic system.The Journal of physiology · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Conditional deletion of IPJournal of gastroenterology · 2025
    Article
  10. CaInflammation and regeneration · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Antihypertensive and ACE-2 Inhibitory Effects ofCardiovascular & hematological agents in medicinal chemistry · 2024
    Article
  15. Article
  16. Review
  17. Loss of IP3R-BKInternational journal of molecular sciences · 2023
    Article
  18. Orai, RyR, and IPCommunications biology · 2023
    Article
  19. Article
  20. IPiScience · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Qingsong LinDrug Discovery Center, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China.
Guiling ZhaoCenter for Biomedical Engineering and Technology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Xi FangUniversity of California San Diego, School of Medicine, Department of Medicine, La Jolla, California, USA.
Xiaohong PengDrug Discovery Center, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China.
Huayuan TangDrug Discovery Center, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China.
Hong WangDrug Discovery Center, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China.
Ran JingXiangya Hospital, Central South University, Changsha, China.
Jie LiuDepartment of Pathophysiology, School of Medicine, Shenzhen University, Shenzhen, China.
W Jonathan LedererCenter for Biomedical Engineering and Technology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Ju ChenUniversity of California San Diego, School of Medicine, Department of Medicine, La Jolla, California, USA.
Kunfu OuyangDrug Discovery Center, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China.
Peking University · CNUniversity of Maryland, Baltimore · USCentral South University · CNShenzhen University · CN

Funding

Program AdministrationP01HL080101 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERS, DONALD M · 2006 to 2015
$23.4M
BAG3 in Cardiac function and diseaseR01HL130295 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, JU · 2016 to 2019
$1.6M
Adipocytes and cardiac remodelingR01HL130452 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, JU · 2016 to 2019
$1.6M
Luma in Cardiac Function and DiseaseR01HL123626 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, JU, EVANS, SYLVIA M · 2014 to 2017
$1.5M
NHLBI NIH HHS P01 HL080101NHLBI NIH HHS R01 HL123626NHLBI NIH HHS R01 HL130295NHLBI NIH HHS R01 HL130452
6 · The paper itself

Abstract

Inositol 1, 4, 5-trisphosphate receptor-mediated (IP

Indexed as

Calcium SignalingAnimalsBlood PressureHypertensionInositol 1,4,5-Trisphosphate ReceptorsMaleMiceMice, Inbred C57BLMice, KnockoutMuscle, Smooth, VascularVasoconstrictor AgentsInositol 1,4,5-Trisphosphate ReceptorsVasoconstrictor Agents

Identifiers

PMID27777977
PMCPMC5070959
OpenAlexW2533806983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.